FDA advisers vote against Capricor's Duchenne heart disease therapy
29/07/2026 21:52
FDA advisers vote against Capricor's Duchenne heart disease therapy July 29 (Reuters) - The U.S. FDA's panel of independent advisers on Wednesday voted against the benefits of Capricor Therapeutics' CAPR.O cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystrophy, a rare muscle-wasting disease.
(Reporting by Sahil Pandey and Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure